PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases
Abstract
:1. Introduction
2. Synthesis Method of PLGA M/NPs
2.1. Single and Double Emulsion
2.2. Spray Drying Method
2.3. Precipitation Method
2.4. Coacervation Method
3. Modification of PLGA M/NPs
3.1. Cationic Modification
3.2. Hydrophilic Modification
3.3. Targeting Modification
4. Application of PLGA M/NPs in Respiratory Diseases Treatment
4.1. Application of PLGA M/NPs in Asthma
4.2. Application of PLGA M/NPs in COPD
4.3. Application of PLGA M/NPs in CF
4.4. Application of PLGA M/NPs in ALI/ARDS
4.5. Application of PLGA M/NPs in ARIs
5. Conclusions and Outlook
Author Contributions
Funding
Conflicts of Interest
References
- Chan, Y.; Singh, S.K.; Gulati, M.; Wadhwa, S.; Prasher, P.; Kumar, D.; Kumar, A.P.; Gupta, G.; Kuppusamy, G.; Haghi, M.; et al. Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases. J. Drug Deliv. Sci. Technol. 2022, 74, 103541. [Google Scholar] [CrossRef] [PubMed]
- Hurgobin, B.; De Jong, E.; Bosco, A. Insights into respiratory disease through bioinformatics. Respirology 2018, 23, 1117–1126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levine, S.M.; Marciniuk, D.D. Global impact of respiratory disease: What can we do, together, to make a difference? Chest 2022, 161, 1153–1154. [Google Scholar] [CrossRef] [PubMed]
- Poole, J.A. Asthma is a major noncommunicable disease affecting over 230 million people worldwide and represents the most common chronic disease among children. Int. Immunopharmacol. 2014, 23, 315. [Google Scholar] [CrossRef] [PubMed]
- Maciag, M.C.; Phipatanakul, W. Prevention of asthma targets for intervention. Chest 2020, 158, 913–922. [Google Scholar] [CrossRef]
- Voskamp, A.; Kormelink, T.G.; van Wijk, R.G.; Hiemstra, P.; Taube, C.; de Jong, E.; Smits, H.H. Modulating local airway immune responses to treat allergic asthma: Lessons from experimental models and human studies. Semin. Immunopathol. 2020, 42, 95–110. [Google Scholar] [CrossRef] [Green Version]
- Patton, J.S.; Byron, P.R. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6, 67–74. [Google Scholar] [CrossRef]
- Ahadian, S.; Finbloom, J.A.; Mofidfar, M.; Diltemiz, S.E.; Nasrollahi, F.; Davoodi, E.; Hosseini, V.; Mylonaki, I.; Sangabathuni, S.; Montazerian, H.; et al. Micro and nanoscale technologies in oral drug delivery. Adv. Drug Deliv. Rev. 2020, 157, 37–62. [Google Scholar] [CrossRef]
- Abuhelwa, A.Y.; Williams, D.B.; Upton, R.N.; Foster, D.J.R. Food, gastrointestinal pH, and models of oral drug absorption. Eur. J. Pharm. Biopharm. 2017, 112, 234–248. [Google Scholar] [CrossRef]
- Amara, S.; Bourlieu, C.; Humbert, L.; Rainteau, D.; Carrière, F. Variations in gastrointestinal lipases, pH and bile acid levels with food intake, age and diseases: Possible impact on oral lipid-based drug delivery systems. Adv. Drug Deliv. Rev. 2019, 142, 3–15. [Google Scholar] [CrossRef]
- Luo, C.; Sun, J.; Du, Y.; He, Z. Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy. J. Control Release 2014, 176, 94–103. [Google Scholar] [CrossRef] [PubMed]
- Zhong, W.; Zhang, X.; Zeng, Y.; Lin, D.; Wu, J. Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 2021, 14, 2067–2089. [Google Scholar] [CrossRef] [PubMed]
- Sorino, C.; Negri, S.; Spanevello, A.; Visca, D.; Scichilone, N. Inhalation therapy devices for the treatment of obstructive lung diseases: The history of inhalers towards the ideal inhaler. Eur. J. Intern. Med. 2020, 75, 15–18. [Google Scholar] [CrossRef]
- Chandel, A.; Goyal, A.K.; Ghosh, G.; Rath, G. Recent advances in aerosolised drug delivery. Biomed. Pharmacother. 2019, 112, 108601. [Google Scholar] [CrossRef] [PubMed]
- Patton, J.S.; Fishburn, C.S.; Weers, J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 2004, 1, 338–344. [Google Scholar] [CrossRef]
- Bassetti, M.; Vena, A.; Russo, A.; Peghin, M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs 2020, 80, 1309–1318. [Google Scholar] [CrossRef]
- Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25, 563–570. [Google Scholar] [CrossRef]
- Johnson, D.C. Airway mucus function and dysfunction. N. Engl. J. Med. 2011, 364, 978. [Google Scholar] [CrossRef] [Green Version]
- Mo, R.; Jiang, T.; Di, J.; Tai, W.; Gu, Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem. Soc. Rev. 2014, 43, 3595–3629. [Google Scholar] [CrossRef]
- Bhattacharyya, A.; Janarthanan, G.; Kim, T.; Taheri, S.; Shin, J.; Kim, J.; Bae, H.C.; Han, H.S.; Noh, I. Modulation of bioactive calcium phosphate micro/nanoparticle size and shape during in situ synthesis of photo-crosslinkable gelatin methacryloyl based nanocomposite hydrogels for 3D bioprinting and tissue engineering. Biomater. Res. 2022, 26, 54. [Google Scholar] [CrossRef]
- Guo, Z.; Liu, Y.; Luo, Y. Mechanisms of carotenoid intestinal absorption and the regulation of dietary lipids: Lipid transporter-mediated transintestinal epithelial pathways. Crit. Rev. Food Sci. Nutr. 2022, 1–26. [Google Scholar] [CrossRef]
- Meng, H.; Ye, W.; Wang, C.; Gao, Z.; Hu, B.; Wang, C. Crystalline micro-nanoparticles enhance cross-linked hydrogels via a confined assembly of chitosan and gamma-cyclodextrin. Carbohydr. Polym. 2022, 298, 120145. [Google Scholar] [CrossRef]
- Swider, E.; Koshkina, O.; Tel, J.; Cruz, L.J.; de Vries, I.J.M.; Srinivas, M. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater. 2018, 73, 38–51. [Google Scholar] [CrossRef]
- Essa, D.; Kondiah, P.P.D.; Choonara, Y.E.; Pillay, V. The design of poly(lactide-co-glycolide) nanocarriers for medical applications. Front Bioeng. Biotechnol. 2020, 8, 48. [Google Scholar] [CrossRef] [PubMed]
- El-Hammadi, M.M.; Arias, J.L. Recent advances in the surface functionalization of PLGA-based nanomedicines. Nanomaterials 2022, 12, 354. [Google Scholar] [CrossRef]
- Papi, A.; Brightling, C.; Pedersen, S.E.; Reddel, H.K. Asthma. Lancet 2018, 391, 783–800. [Google Scholar] [CrossRef]
- Mintz, M.; Barjaktarevic, I.; Mahler, D.A.; Make, B.; Skolnik, N.; Yawn, B.; Zeyzus-Johns, B.; Hanania, N.A. Reducing the risk of mortality in chronic obstructive pulmonary disease with pharmacotherapy: A narrative review. Mayo Clin. Proc. 2023, 98, 301–315. [Google Scholar] [CrossRef] [PubMed]
- Ehre, C.; Ridley, C.; Thornton, D.J. Cystic fibrosis: An inherited disease affecting mucin-producing organs. Int. J. Biochem. Cell Biol. 2014, 52, 136–145. [Google Scholar] [CrossRef]
- Lupu, L.; Palmer, A.; Huber-Lang, M. Inflammation, thrombosis, and destruction: The three-headed cerberus of trauma- and SARS-CoV-2-induced ARDS. Front. Immunol. 2020, 11, 584514. [Google Scholar] [CrossRef]
- Bulla, A.; Hitze, K.L. Acute respiratory infections: A review. Bull. World Health Organ. 1978, 56, 481–498. [Google Scholar]
- El-Hammadi, M.M.; Delgado, A.V.; Melguizo, C.; Prados, J.C.; Arias, J.L. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int. J. Pharm. 2017, 516, 61–70. [Google Scholar] [CrossRef]
- Mohammed, H.A.; Sulaiman, G.M.; Anwar, S.S.; Tawfeeq, A.T.; Khan, R.A.; Mohammed, S.A.A.; Al-Omar, M.S.; Alsharidah, M.; Rugaie, O.A.; Al-Amiery, A.A. Quercetin against MCF7 and CAL51 breast cancer cell lines: Apoptosis, gene expression and cytotoxicity of nano-quercetin. Nanomedicine 2021, 16, 1937–1961. [Google Scholar] [CrossRef]
- Otaka, E.; Ooi, T.; Suzuki, K. Examination of protein sequence homologies. VI. The evolution of Escherichia coli L7/L12 equivalent ribosomal proteins (‘A’ proteins), and the tertiary structure. Protein Seq. Data Anal. 1989, 2, 395–402. [Google Scholar]
- Hill, M.; Cunningham, R.N.; Hathout, R.M.; Johnston, C.; Hardy, J.G.; Migaud, M.E. Formulation of antimicrobial tobramycin loaded PLGA nanoparticles via complexation with AOT. J. Funct. Biomater. 2019, 10, 26. [Google Scholar] [CrossRef] [Green Version]
- Pandey, P.; Rahman, M.; Bhatt, P.C.; Beg, S.; Paul, B.; Al-Abbasi, F.A.; Hafeez, A.; Nadeem, M.S.; Baothman, O.; Anwar, F.; et al. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine 2018, 13, 849–870. [Google Scholar] [CrossRef]
- Abdelkader, D.H.; Abosalha, A.K.; Khattab, M.A.; Aldosari, B.N.; Almurshedi, A.S. A novel sustained anti-inflammatory effect of atorvastatin-calcium PLGA nanoparticles: In vitro optimization and in vivo evaluation. Pharmaceutics 2021, 13, 1658. [Google Scholar] [CrossRef] [PubMed]
- Boltnarova, B.; Kubackova, J.; Skoda, J.; Stefela, A.; Smekalova, M.; Svacinova, P.; Pavkova, I.; Dittrich, M.; Scherman, D.; Zbytovska, J.; et al. PLGA based nanospheres as a potent macrophage-specific drug delivery system. Nanomaterials 2021, 11, 749. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Li, P.; Tran, T.T.; Zhang, J.; Kong, L. Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer. Nanomaterials 2016, 6, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Astete, C.E.; Sabliov, C.M. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 2006, 17, 247–289. [Google Scholar] [CrossRef]
- Makadia, H.K.; Siegel, S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3, 1377–1397. [Google Scholar] [CrossRef]
- Garbayo, E.; Ansorena, E.; Blanco-Prieto, M.J. Brain drug delivery systems for neurodegenerative disorders. Curr. Pharm. Biotechnol. 2012, 13, 2388–2402. [Google Scholar] [CrossRef]
- Fernandez, M.; Barcia, E.; Fernández-Carballido, A.; Garcia, L.; Slowing, K.; Negro, S. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson’s disease. Int. J. Pharm. 2012, 438, 266–278. [Google Scholar] [CrossRef]
- Formiga, F.R.; Pelacho, B.; Garbayo, E.; Abizanda, G.; Gavira, J.J.; Simon-Yarza, T.; Mazo, M.; Tamayo, E.; Jauquicoa, C.; Ortiz-de-Solorzano, C.; et al. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J. Control Release 2010, 147, 30–37. [Google Scholar] [CrossRef]
- Ospina-Villa, J.D.; Gómez-Hoyos, C.; Zuluaga-Gallego, R.; Triana-Chávez, O. Encapsulation of proteins from Leishmania panamensis into PLGA particles by a single emulsion-solvent evaporation method. J. Microbiol. Methods 2019, 162, 1–7. [Google Scholar] [CrossRef]
- Zhang, X.; Intra, J.; Salem, A.K. Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J. Microencapsul. 2008, 25, 1–12. [Google Scholar] [CrossRef]
- Azizi, M.; Farahmandghavi, F.; Joghataei, M.T.; Zandi, M.; Imani, M.; Bakhtiari, M.; Omidian, H. ChABC-loaded PLGA nanoparticles: A comprehensive study on biocompatibility, functional recovery, and axonal regeneration in animal model of spinal cord injury. Int. J. Pharm. 2020, 577, 119037. [Google Scholar] [CrossRef]
- Davoudi, Z.; Peroutka-Bigus, N.; Bellaire, B.; Wannemuehler, M.; Barrett, T.A.; Narasimhan, B.; Wang, Q. Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases. J. Biomed. Mater. Res. A. 2018, 106, 876–886. [Google Scholar] [CrossRef]
- Lee, P.W.; Pokorski, J.K. Poly(lactic-co-glycolic acid) devices: Production and applications for sustained protein delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2018, 10, e1516. [Google Scholar] [CrossRef]
- Wan, F.; Yang, M. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. Int. J. Pharm. 2016, 498, 82–95. [Google Scholar] [CrossRef]
- Nie, H.; Lee, L.Y.; Tong, H.; Wang, C. PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: New carriers for DNA delivery. J. Control Release 2008, 129, 207–214. [Google Scholar] [CrossRef]
- Ding, D.; Zhu, Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater. Sci. Eng. C Mater. Biol. Appl. 2018, 92, 1041–1060. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Meisner, D.; Kwong, E.; Wu, X.Y.; Johnston, M.R. A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. Biomaterials 2007, 28, 3236–3244. [Google Scholar] [CrossRef]
- Wolburg, H.; Neuhaus, J.; Kniesel, U.; Krauss, B.; Schmid, E.M.; Ocalan, M.; Farrell, C.; Risau, W. Modulation of tight junction structure in blood-brain barrier endothelial cells. Effects of tissue culture, second messengers and cocultured astrocytes. J. Cell Sci. 1994, 107 Pt 5, 1347–1357. [Google Scholar] [CrossRef] [PubMed]
- Spindler, L.M.; Feuerhake, A.; Ladel, S.; Günday, C.; Flamm, J.; Günday-Türeli, N.; Türeli, E.; Tovar, G.E.M.; Schindowski, K.; Gruber-Traub, C. Nano-in-micro-particles consisting of PLGA nanoparticles embedded in chitosan microparticles via spray-drying enhances their uptake in the olfactory mucosa. Front. Pharmacol. 2021, 12, 732954. [Google Scholar] [CrossRef]
- El-Maghawry, E.; Tadros, M.I.; Elkheshen, S.A.; Abd-Elbary, A. Eudragit((R))-S100 coated PLGA nanoparticles for colon targeting of etoricoxib: Optimization and pharmacokinetic assessments in healthy human volunteers. Int. J. Nanomed. 2020, 15, 3965–3980. [Google Scholar] [CrossRef]
- Yan, X.; Bernard, J.; Ganachaud, F. Nanoprecipitation as a simple and straightforward process to create complex polymeric colloidal morphologies. Adv. Colloid Interface Sci. 2021, 294, 102474. [Google Scholar] [CrossRef] [PubMed]
- Lepeltier, E.; Bourgaux, C.; Couvreur, P. Nanoprecipitation and the “Ouzo effect”: Application to drug delivery devices. Adv. Drug Deliv. Rev. 2014, 71, 86–97. [Google Scholar] [CrossRef] [PubMed]
- Govender, T.; Stolnik, S.; Garnett, M.C.; Illum, L.; Davis, S.S. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J. Control Release 1999, 57, 171–185. [Google Scholar] [CrossRef]
- Al-Humaidi, R.B.; Fayed, B.; Shakartalla, S.B.; Jagal, J.; Jayakumar, M.N.; Shareef, Z.M.A.; Sharif, S.I.; Noreddin, A.; Semreen, M.H.; Omar, H.A.; et al. Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles. Life Sci. 2022, 305, 120778. [Google Scholar] [CrossRef]
- Patra, A.; Satpathy, S.; Naik, P.K.; Kazi, M.; Hussain, M.D. Folate receptor-targeted PLGA-PEG nanoparticles for enhancing the activity of genistein in ovarian cancer. Artif. Cells Nanomed. Biotechnol. 2022, 50, 228–239. [Google Scholar] [CrossRef]
- Wang, R.; Bao, Q.; Clark, A.G.; Wang, Y.; Zhang, S.; Burgess, D.J. Characterization and in vitro release of minocycline hydrochloride microspheres prepared via coacervation. Int. J. Pharm. 2022, 628, 122292. [Google Scholar] [CrossRef] [PubMed]
- Butreddy, A.; Gaddam, R.P.; Kommineni, N.; Dudhipala, N.; Voshavar, C. PLGA/PLA-based long-acting injectable depot microspheres in clinical use: Production and characterization overview for protein/peptide delivery. Int. J. Mol. Sci. 2021, 22, 8884. [Google Scholar] [CrossRef] [PubMed]
- Park, P.I.P.; Makoid, M.; Jonnalagadda, S. The design of flexible ciprofloxacin-loaded PLGA implants using a reversed phase separation/coacervation method. Eur. J. Pharm. Biopharm. 2011, 77, 233–239. [Google Scholar] [CrossRef]
- Mu, L.; Feng, S.S. Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J. Control Release 2001, 76, 239–254. [Google Scholar] [CrossRef]
- Gavini, E.; Chetoni, P.; Cossu, M.; Alvarez, M.G.; Saettone, M.F.; Giunchedi, P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: In vitro/in vivo studies. Eur. J. Pharm. Biopharm. 2004, 57, 207–212. [Google Scholar] [CrossRef]
- Sastre, R.L.; Olmo, R.; Teijon, C.; Muniz, E.; Teijon, J.M.; Blanco, M.D. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers. Int. J. Pharm. 2007, 338, 180–190. [Google Scholar] [CrossRef]
- Almoustafa, H.A.; Alshawsh, M.A.; Chik, Z. Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method. Int. J. Pharm. 2017, 533, 275–284. [Google Scholar] [CrossRef]
- Bodmeier, R.; Chen, H.; Tyle, P.; Jarosz, P. Spontaneous formation of drug-containing acrylic nanoparticles. J. Microencapsul. 1991, 8, 161–170. [Google Scholar] [CrossRef]
- Graham, P.D.; Brodbeck, K.J.; McHugh, A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control Release 1999, 58, 233–245. [Google Scholar] [CrossRef]
- Thomasin, C.; Ho, N.T.; Merkle, H.P.; Gander, B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations. J. Pharm. Sci. 1998, 87, 259–268. [Google Scholar] [CrossRef]
- Edelman, R.; Russell, R.G.; Losonsky, G.; Tall, B.D.; Tacket, C.O.; Levine, M.M.; Lewis, D.H. Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 1993, 11, 155–158. [Google Scholar] [CrossRef] [PubMed]
- Kotta, S.; Aldawsari, H.M.; Badr-Eldin, S.M.; Binmahfouz, L.S.; Bakhaidar, R.B.; Sreeharsha, N.; Nair, A.B.; Ramnarayanan, C. Lung targeted lipopolymeric microspheres of dexamethasone for the treatment of ARDS. Pharmaceutics 2021, 13, 1347. [Google Scholar] [CrossRef] [PubMed]
- Almukainzi, M.; El-Masry, T.; Negm, W.; Elekhnawy, E.; Saleh, A.; Sayed, A.; Khattab, M.; Abdelkader, D. Gentiopicroside PLGA Nanospheres: Fabrication, in vitro Characterization, Antimicrobial Action, and in vivo Effect for Enhancing Wound Healing in Diabetic Rats. Int. J. Nanomed. 2022, 17, 1203–1225. [Google Scholar] [CrossRef]
- Aragon-Navas, A.; Rodrigo, M.J.; Garcia-Herranz, D.; Martinez, T.; Subias, M.; Mendez, S.; Ruberte, J.; Pampalona, J.; Bravo-Osuna, I.; Garcia-Feijoo, J.; et al. Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres. Drug Deliv. 2022, 29, 2357–2374. [Google Scholar] [CrossRef]
- Zheng, D.; Wan, C.; Yang, H.; Xu, L.; Dong, Q.; Du, C.; Du, J.; Li, F. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment. Int. J. Nanomed. 2020, 15, 10007–10028. [Google Scholar] [CrossRef]
- Zhu, K.; Yao, Y.; Wang, K.; Shao, F.; Zhu, Z.; Song, Y.; Zhou, Z.; Jiang, D.; Lan, X.; Qin, C. Berberin sustained-release nanoparticles were enriched in infarcted rat myocardium and resolved inflammation. J. Nanobiotechnol. 2023, 21, 33. [Google Scholar] [CrossRef]
- Cappiello, F.; Casciaro, B.; Loffredo, M.R.; Puglisi, E.; Lin, Q.; Yang, D.; Conte, G.; d’Angelo, I.; Ungaro, F.; Ferrera, L.; et al. Pulmonary safety profile of esc peptides and esc-peptide-loaded poly(lactide-co-glycolide) nanoparticles: A promising therapeutic approach for local treatment of lung infectious diseases. Pharmaceutics 2022, 14, 2297. [Google Scholar] [CrossRef]
- Casciaro, B.; D’Angelo, I.; Zhang, X.; Loffredo, M.R.; Conte, G.; Cappiello, F.; Quaglia, F.; Di, Y.-P.P.; Ungaro, F.; Mangoni, M.L. Poly(lactide-co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against Pseudomonas aeruginosa lung infection: In vitro and in vivo studies. Biomacromolecules 2019, 20, 1876–1888. [Google Scholar] [CrossRef]
- Qu, S.; Zhao, L.; Zhu, J.; Wang, C.; Dai, C.; Guo, H.; Hao, Z. Preparation and testing of cefquinome-loaded poly lactic-co-glycolic acid microspheres for lung targeting. Drug Deliv. 2017, 24, 745–751. [Google Scholar] [CrossRef] [Green Version]
- SreeHarsha, N.; Venugopala, K.N.; Nair, A.B.; Roopashree, T.S.; Attimarad, M.; Hiremath, J.G.; Al-Dhubiab, B.; Ramnarayanan, C.; Shinu, P.; Handral, M.; et al. An efficient, lung-targeted, drug-delivery system to treat asthma via microparticles. Drug Des. Dev. Ther. 2019, 13, 4389–4403. [Google Scholar] [CrossRef] [Green Version]
- Hoyle, G.W.; Chen, J.; Schlueter, C.F.; Mo, Y.; Humphrey, D.M., Jr.; Rawson, G.; Nino, J.A.; Carson, K.H. Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation. Toxicol. Appl. Pharmacol. 2016, 298, 9–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nassar, T.; Rohald, A.; Naraykin, N.; Barasch, D.; Amsalem, O.; Prabhu, P.; Kotler, M.; Benita, S. Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. J. Drug Target 2019, 27, 590–600. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.; Wu, S.; Xie, W.; Cheng, A.; Yang, L.; Hou, Z.; Jin, X. Dual-drug loaded nanoneedles with targeting property for efficient cancer therapy. J. Nanobiotechnol. 2017, 15, 91. [Google Scholar] [CrossRef] [Green Version]
- Maleki, H.; Hosseini Najafabadi, M.R.; Webster, T.J.; Hadjighassem, M.R.; Sadroddiny, E.; Ghanbari, H.; Khosravani, M.; Adabi, M. Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma. Int. J. Pharm. 2021, 604, 120722. [Google Scholar] [CrossRef]
- Bairagi, U.; Mittal, P.; Singh, J.; Mishra, B. Preparation, characterization, and in vivo evaluation of nano formulations of ferulic acid in diabetic wound healing. Drug Dev. Ind. Pharm. 2018, 44, 1783–1796. [Google Scholar] [CrossRef]
- Katara, R.; Sachdeva, S.; Majumdar, D.K. Enhancement of ocular efficacy of aceclofenac using biodegradable PLGA nanoparticles: Formulation and characterization. Drug Deliv. Transl. Res. 2017, 7, 632–641. [Google Scholar] [CrossRef]
- Ma, X.; Kuang, L.; Yin, Y.; Tang, L.; Zhang, Y.; Fan, Q.; Wang, B.; Dong, Z.; Wang, W.; Yin, T.; et al. Tumor-antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano 2023, 17, 2341–2355. [Google Scholar] [CrossRef] [PubMed]
- Oh, Y.J.; Lee, J.; Seo, J.Y.; Rhim, T.; Kim, S.H.; Yoon, H.J.; Lee, K.Y. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J. Control Release 2011, 150, 56–62. [Google Scholar] [CrossRef]
- Pálinkó-Biró, E.; Rónaszèki, G.; Merkle, H.P.; Gander, B. Release kinetics and immunogenicity of parvovirus microencapsulated in PLA/PLGA microspheres. Int. J. Pharm. 2001, 221, 153–157. [Google Scholar] [CrossRef]
- Johansen, P.; Moon, L.; Tamber, H.; Merkle, H.P.; Gander, B.; Sesardic, D. Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 1999, 18, 209–215. [Google Scholar] [CrossRef]
- Kolge, H.; Patil, G.; Jadhav, S.; Ghormade, V. A pH-tuned chitosan-PLGA nanocarrier for fluconazole delivery reduces toxicity and improves efficacy against resistant Candida. Int. J. Biol. Macromol. 2023, 227, 453–461. [Google Scholar] [CrossRef] [PubMed]
- Fernández-Álvarez, F.; Caro, C.; García-García, G.; García-Martín, M.L.; Arias, J.L. Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer. J. Mater. Chem. B 2021, 9, 4963–4980. [Google Scholar] [CrossRef]
- Meena, R.; Kumar, S.; Kumar, R.; Gaharwar, U.S.; Rajamani, P. PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells). Biomed. Pharmacother. 2017, 94, 944–954. [Google Scholar] [CrossRef] [PubMed]
- Kang, B.-S.; Choi, J.-S.; Lee, S.-E.; Lee, J.-K.; Kim, T.-H.; Jang, W.S.; Tunsirikongkon, A.; Kim, J.-K.; Park, J.-S. Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. Carbohydr. Polym. 2017, 159, 39–47. [Google Scholar] [CrossRef]
- Pawar, D.; Mangal, S.; Goswami, R.; Jaganathan, K.S. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur. J. Pharm. Biopharm. 2013, 85 Pt A, 550–559. [Google Scholar] [CrossRef]
- Ibrahim, M.; Ramadan, E.; Elsadek, N.E.; Emam, S.E.; Shimizu, T.; Ando, H.; Ishima, Y.; Elgarhy, O.H.; Sarhan, H.A.; Hussein, A.K.; et al. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J. Control. Release 2022, 351, 215–230. [Google Scholar] [CrossRef]
- Vllasaliu, D.; Fowler, R.; Stolnik, S. PEGylated nanomedicines: Recent progress and remaining concerns. Expert Opin. Drug Deliv. 2014, 11, 139–154. [Google Scholar] [CrossRef]
- Owens, D.E., 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93–102. [Google Scholar] [CrossRef]
- Amoozgar, Z.; Park, J.; Lin, Q.; Yeo, Y. Low Molecular-Weight Chitosan as a pH-Sensitive Stealth Coating for Tumor-Specific Drug Delivery. Mol. Pharm. 2012, 9, 1262–1270. [Google Scholar] [CrossRef] [Green Version]
- Majumder, J.; Minko, T. Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Adv. Ther. 2021, 4, 2000203. [Google Scholar] [CrossRef]
- Koerner, J.; Horvath, D.; Groettrup, M. Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)—Mediated Anti-tumor Therapy. Front. Immunol. 2019, 10, 707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Y.; Ding, Y.; Fan, B.; Wang, Y.; Mao, Z.; Wang, W.; Wu, J. Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis. J. Control. Release 2020, 321, 463–474. [Google Scholar] [CrossRef]
- Zhang, C.Y.; Lin, W.; Gao, J.; Shi, X.; Davaritouchaee, M.; Nielsen, A.E.; Mancini, R.J.; Wang, Z. pH-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury. ACS Appl. Mater. Interfaces 2019, 11, 16380–16390. [Google Scholar] [CrossRef]
- Spence, S.; Greene, M.K.; Fay, F.; Hams, E.; Saunders, S.P.; Hamid, U.; Fitzgerald, M.; Beck, J.; Bains, B.K.; Smyth, P.; et al. Targeting Siglecs with a sialic acid–decorated nanoparticle abrogates inflammation. Sci. Transl. Med. 2015, 7, 303ra140. [Google Scholar] [CrossRef] [Green Version]
- Prakash, Y.S.; Halayko, A.J.; Gosens, R.; Panettieri, R.A., Jr.; Camoretti-Mercado, B.; Penn, R.B.; ATS Assembly on Respiratory Structure and Function. An official american thoracic society research statement: Current challenges facing research and therapeutic advances in airway remodeling. Am. J. Respir. Crit Care Med. 2017, 195, e4–e19. [Google Scholar] [CrossRef]
- Stern, J.; Pier, J.; Litonjua, A.A. Asthma epidemiology and risk factors. Semin. Immunopathol. 2020, 42, 5–15. [Google Scholar] [CrossRef]
- Zhao, Y.; Wang, Y.; Ran, F.; Cui, Y.; Liu, C.; Zhao, Q.; Gao, Y.; Wang, D.; Wang, S. A comparison between sphere and rod nanoparticles regarding their in vivo biological behavior and pharmacokinetics. Sci. Rep. 2017, 7, 4131. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.-Y.; Ferrari, M.; Decuzzi, P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009, 20, 495101. [Google Scholar] [CrossRef]
- Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S.-Y.; Chiappini, C.; Liu, X.; Ferrari, M. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 2010, 141, 320–327. [Google Scholar] [CrossRef]
- Park, J.Y.; Chu, G.E.; Park, S.; Park, C.; Aryal, S.; Kang, W.J.; Gil Cho, W.; Key, J. Therapeutic Efficacy of Curcumin Enhanced by Microscale Discoidal Polymeric Particles in a Murine Asthma Model. Pharmaceutics 2020, 12, 739. [Google Scholar] [CrossRef]
- Patel, B.; Rashid, J.; Ahsan, F. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs. Eur. J. Pharm. Sci. 2017, 96, 560–570. [Google Scholar] [CrossRef]
- Perry, J.L.; Reuter, K.G.; Kai, M.P.; Herlihy, K.P.; Jones, S.W.; Luft, J.C.; Napier, M.; Bear, J.E.; DeSimone, J.M. PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and Pharmacokinetics. Nano Lett. 2012, 12, 5304–5310. [Google Scholar] [CrossRef]
- Li, J.; Zheng, H.; Xu, E.-Y.; Moehwald, M.; Chen, L.; Zhang, X.; Mao, S. Inhalable PLGA microspheres: Tunable lung retention and systemic exposure via polyethylene glycol modification. Acta Biomater. 2021, 123, 325–334. [Google Scholar] [CrossRef] [PubMed]
- Akdis, M.; Akdis, C.A. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov. 2009, 8, 645–660. [Google Scholar] [CrossRef]
- Akdis, C.A. Therapies for allergic inflammation: Refining strategies to induce tolerance. Nat. Med. 2012, 18, 736–749. [Google Scholar] [CrossRef]
- Ma, A.; Malynn, B.A. A20: Linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 2012, 12, 774–785. [Google Scholar] [CrossRef] [Green Version]
- Luo, X.-Q.; Zhong, J.-W.; Qiu, S.-Y.; Zhi, M.; Yang, L.-Q.; Zhou, Y.-L.; Zhou, F.-X.; Yang, P.-C.; Liu, D.-B.; Mo, L.-H. A20-OVA Nanoparticles Inhibit Allergic Asthma in a Murine Model. Inflammation 2020, 43, 953–961. [Google Scholar] [CrossRef]
- Li, X.; Zhang, Y.; Pei, W.; Zhang, M.; Yang, H.; Zhong, M.; Kong, X.; Xu, Y.; Zhu, X.; Chen, T.; et al. LncRNA Dnmt3aos regulates Dnmt3a expression leading to aberrant DNA methylation in macrophage polarization. FASEB J. 2020, 34, 5077–5091. [Google Scholar] [CrossRef] [Green Version]
- Pei, W.; Li, X.; Bi, R.; Zhang, X.; Zhong, M.; Yang, H.; Zhang, Y.; Lv, K. Exosome membrane-modified M2 macrophages targeted nanomedicine: Treatment for allergic asthma. J. Control. Release 2021, 338, 253–267. [Google Scholar] [CrossRef]
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [Google Scholar] [CrossRef] [Green Version]
- Matera, M.G.; Page, C.P.; Cazzola, M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 2011, 32, 495–506. [Google Scholar] [CrossRef] [PubMed]
- Barnes, P.J. Inhaled Corticosteroids in COPD: A Controversy. Respiration 2010, 80, 89–95. [Google Scholar] [CrossRef]
- Gordon, S.; Taylor, P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5, 953–964. [Google Scholar] [CrossRef] [PubMed]
- Martinez, F.O.; Gordon, S.; Locati, M.; Mantovani, A. Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression. J. Immunol. 2006, 177, 7303–7311. [Google Scholar] [CrossRef] [Green Version]
- Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958–969. [Google Scholar] [CrossRef]
- van Noort, J.M.; Bsibsi, M.; Nacken, P.J.; Gerritsen, W.H.; Amor, S.; Holtman, I.R.; Boddeke, E.; van Ark, I.; Leusink-Muis, T.; Folkerts, G.; et al. Activation of an immune-regulatory macrophage response and inhibition of lung inflammation in a mouse model of COPD using heat-shock protein alpha B-crystallin-loaded PLGA microparticles. Biomaterials 2013, 34, 831–840. [Google Scholar] [CrossRef]
- Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806–811. [Google Scholar] [CrossRef]
- Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals 2013, 6, 223–250. [Google Scholar] [CrossRef] [Green Version]
- Kishore, A.; Borucka, J.; Petrkova, J.; Petrek, M. Novel Insights into miRNA in Lung and Heart Inflammatory Diseases. Mediat. Inflamm. 2014, 2014, 259131. [Google Scholar] [CrossRef]
- Ebrahimi, A.; Sadroddiny, E. MicroRNAs in lung diseases: Recent findings and their pathophysiological implications. Pulm. Pharmacol. Ther. 2015, 34, 55–63. [Google Scholar] [CrossRef]
- Sato, T.; Liu, X.; Nelson, A.; Nakanishi, M.; Kanaji, N.; Wang, X.; Kim, M.; Li, Y.; Sun, J.; Michalski, J.; et al. Reduced miR-146a Increases Prostaglandin E2 in Chronic Obstructive Pulmonary Disease Fibroblasts. Am. J. Respir. Crit. Care Med. 2010, 182, 1020–1029. [Google Scholar] [CrossRef] [Green Version]
- Saxena, J.; Bisen, M.; Misra, A.; Srivastava, V.K.; Kaushik, S.; Siddiqui, A.J.; Mishra, N.; Singh, A.; Jyoti, A. Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects. BioMed Res. Int. 2022, 2022, 5058121. [Google Scholar] [CrossRef]
- Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541–555. [Google Scholar] [CrossRef]
- Mohamed, A.; Pekoz, A.Y.; Ross, K.; Hutcheon, G.A.; Saleem, I.Y. Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD. Int. J. Pharm. 2019, 569, 118524. [Google Scholar] [CrossRef]
- Vij, N.; Min, T.; Bodas, M.; Gorde, A.; Roy, I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine 2016, 12, 2415–2427. [Google Scholar] [CrossRef]
- Endres, T.M.; Konstan, M.W. What Is Cystic Fibrosis? J. Am. Med. Assoc. 2022, 327, 191. [Google Scholar] [CrossRef]
- Ooi, C.Y.; Durie, P.R. Cystic fibrosis from the gastroenterologist’s perspective. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 175–185. [Google Scholar] [CrossRef]
- Elborn, J.S. Cystic fibrosis. Lancet 2016, 388, 2519–2531. [Google Scholar] [CrossRef]
- Ratjen, F.; Bell, S.C.; Rowe, S.M.; Goss, C.H.; Quittner, A.L.; Bush, A. Cystic fibrosis. Nat. Rev. Dis. Prim. 2015, 1, 15010. [Google Scholar] [CrossRef]
- Heijerman, H. Infection and inflammation in cystic fibrosis: A short review. J. Cyst. Fibros. 2005, 4, 3–5. [Google Scholar] [CrossRef] [Green Version]
- Høiby, N. Understanding bacterial biofilms in patients with cystic fibrosis: Current and innovative approaches to potential therapies. J. Cyst. Fibros. 2002, 1, 249–254. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Pornpattananangkul, D.; Hu, C.-M.; Huang, C.-M. Development of Nanoparticles for Antimicrobial Drug Delivery. Curr. Med. Chem. 2010, 17, 585–594. [Google Scholar] [CrossRef] [Green Version]
- Lakshminarayanan, R.; Ye, E.; Young, D.J.; Li, Z.; Loh, X.J. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens. Adv. Healthc. Mater. 2018, 7, 1701400. [Google Scholar] [CrossRef] [Green Version]
- Türeli, N.G.; Torge, A.; Juntke, J.; Schwarz, B.C.; Schneider-Daum, N.; Türeli, A.E.; Lehr, C.-M.; Schneider, M. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur. J. Pharm. Biopharm. 2017, 117, 363–371. [Google Scholar] [CrossRef]
- McEwan, D.L.; Kirienko, N.V.; Ausubel, F.M. Host Translational Inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an Immune Response in Caenorhabditis elegans. Cell Host Microbe 2012, 11, 364–374. [Google Scholar] [CrossRef] [Green Version]
- Weber, A.; Zimmermann, C.; Mausberg, A.K.; Dehmel, T.; Kieseier, B.C.; Hartung, H.; Hofstetter, H.H. Pseudomonas aeruginosa and its bacterial components influence the cytokine response in thymocytes and splenocytes. Infect. Immun. 2016, 84, 1413–1423. [Google Scholar] [CrossRef] [Green Version]
- Zanjani, L.S.; Shapouri, R.; Dezfulian, M.; Mahdavi, M.; Ardestani, M.S. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: Protectivity in murine model. World J. Microbiol. Biotechnol. 2019, 35, 94. [Google Scholar] [CrossRef]
- Kortright, K.E.; Chan, B.K.; Koff, J.L.; Turner, P.E. Phage therapy: A renewed approach tocombat antibiotic-resistant bacteria. Cell Host Microbe 2019, 25, 219–232. [Google Scholar] [CrossRef] [Green Version]
- Donlan, R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 2009, 17, 66–72. [Google Scholar] [CrossRef]
- Millette, G.; Langlois, J.; Brouillette, E.; Frost, E.H.; Cantin, A.M.; Malouin, F. Despite antagonism in vitro, Pseudomonas aeruginosa enhances Staphylococcus aureus colonization in a murine lung infection model. Front. Microbiol. 2019, 10, 2880. [Google Scholar] [CrossRef] [Green Version]
- Kalelkar, P.P.; Moustafa, D.A.; Riddick, M.; Goldberg, J.B.; McCarty, N.A.; García, A.J. Bacteriophage-loaded poly(lactic-co-glycolic acid) microparticles mitigate Staphylococcus aureus infection and cocultures of Staphylococcus aureus and Pseudomonas aeruginosa. Adv. Healthc. Mater. 2022, 11, e2102539. [Google Scholar] [CrossRef]
- Dhooghe, B.; Noël, S.; Huaux, F.; Leal, T. Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies. Clin. Biochem. 2014, 47, 539–546. [Google Scholar] [CrossRef]
- Duncan, G.A.; Jung, J.; Hanes, J.; Suk, J.S. The mucus barrier to inhaled gene therapy. Mol. Ther. 2016, 24, 2043–2053. [Google Scholar] [CrossRef] [Green Version]
- Ma, J.; Rubin, B.K.; Voynow, J.A. Mucins, mucus, and goblet cells. Chest 2018, 154, 169–176. [Google Scholar] [CrossRef]
- Garcia-Diaz, M.; Birch, D.; Wan, F.; Nielsen, H.M. The role of mucus as an invisible cloak to transepithelial drug delivery by nanoparticles. Adv. Drug Deliv. Rev. 2018, 124, 107–124. [Google Scholar] [CrossRef]
- Wine, J.J.; Hansson, G.C.; König, P.; Joo, N.S.; Ermund, A.; Pieper, M. Progress in understanding mucus abnormalities in cystic fibrosis airways. J. Cyst. Fibros. 2018, 17, S35–S39. [Google Scholar] [CrossRef] [Green Version]
- Bear, C.E. 50 years ago in the Journal of Pediatrics: The effect of N-acetylcysteine on the viscosity of tracheobronchial secretions in cystic fibrosis of the pancreas. J. Pediatr. 2013, 162, 85. [Google Scholar] [CrossRef]
- Cristallini, C.; Barbani, N.; Ventrelli, L.; Summa, L.; Filippi, S.; Capelôa, T.; Vitale, E.; Albera, C.; Messore, B.; Giachino, C. Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 95, 19–28. [Google Scholar] [CrossRef]
- Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342, 1334–1349. [Google Scholar] [CrossRef]
- Bellani, G.; Laffey, J.G.; Pham, T.; Fan, E.; Brochard, L.; Esteban, A.; Gattinoni, L.; Haren, F.V.; Larsson, A.; McAuley, D.F. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. J. Am. Med. Assoc. 2016, 315, 788–800. [Google Scholar] [CrossRef]
- Liu, C.; Xiao, K.; Xie, L. Advances in the use of exosomes for the treatment of ALI/ARDS. Front. Immunol. 2022, 13, 971189. [Google Scholar] [CrossRef]
- Fan, E.; Brodie, D.; Slutsky, A.S. Acute respiratory distress syndrome: Advances in diagnosis and treatment. J. Am. Med. Assoc. 2018, 319, 698–710. [Google Scholar] [CrossRef]
- Villar, J.; Ferrando, C.; Martínez, D.; Ambrós, A.; Muñoz, T.; Soler, J.A.; Aguilar, G.; Alba, F.; González-Higueras, E.; Conesa, L.A.; et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir. Med. 2020, 8, 267–276. [Google Scholar] [CrossRef]
- Waljee, A.K.; Rogers, M.A.M.; Lin, P.; Singal, A.G.; Stein, J.D.; Marks, R.M.; Ayanian, J.Z.; Nallamothu, B.K. Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study. Br. Med. J. 2017, 357, j1415. [Google Scholar] [CrossRef] [Green Version]
- Nourshargh, S.; Alon, R. Leukocyte migration into inflamed tissues. Immunity 2014, 41, 694–707. [Google Scholar] [CrossRef] [Green Version]
- Park, J.H.; Jiang, Y.; Zhou, J.; Gong, H.; Mohapatra, A.; Heo, J.; Gao, W.; Fang, R.H.; Zhang, L. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Sci. Adv. 2021, 7, eabf7820. [Google Scholar] [CrossRef]
- Lang, J.D.; McArdle, P.G.; O’Reilly, P.J.; Matalon, S. Oxidant-antioxidant balance in acute lung injury. Chest 2002, 122, 314S–320S. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, L.T.; Frey, H.; Nastase, M.; Tredup, C.; Hoffmann, A.; Poluzzi, C.; Zeng-Brouwers, J.; Manon-Jensen, T.; Schröder, K. Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1beta synthesis. Matrix Biol. 2016, 49, 61–81. [Google Scholar] [CrossRef]
- Jin, F.; Liu, D.; Yu, H.; Qi, J.; You, Y.; Xu, X.; Kang, X.; Wang, X.; Lu, K.; Ying, X.; et al. Sialic acid-functionalized PEG-PLGA microspheres loading mitochondrial-targeting-modified curcumin for acute lung injury therapy. Mol. Pharm. 2019, 16, 71–85. [Google Scholar] [CrossRef]
- de Menezes, B.R.C.; Rodrigues, K.F.; Schatkoski, V.M.; Pereira, R.M.; Ribas, R.G.; Montanheiro, T.L.D.A.; Thim, G.P. Current advances in drug delivery of nanoparticles for respiratory disease treatment. J. Mater. Chem. B 2021, 9, 1745–1761. [Google Scholar] [CrossRef]
- Piters, W.A.A.D.S.; Binkowska, J.; Bogaert, D. Early life microbiota and respiratory tract infections. Cell Host Microbe 2020, 28, 223–232. [Google Scholar] [CrossRef]
- Tali, S.H.S.; LeBlanc, J.J.; Sadiq, Z.; Oyewunmi, O.D.; Camargo, C.; Nikpour, B.; Armanfard, N.; Sagan, S.M.; Jahanshahi-Anbuhi, S. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin. Microbiol. Rev. 2021, 34, e00228-20. [Google Scholar] [CrossRef]
- Dhama, K.; Khan, S.; Tiwari, R.; Sircar, S.; Bhat, S.; Malik, Y.S.; Singh, K.P.; Chaicumpa, W.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. Coronavirus disease 2019-COVID-19. Clin. Microbiol. Rev. 2020, 33, e00028-20. [Google Scholar] [CrossRef]
- Wiersinga, W.J.; Rhodes, A.; Cheng, A.C.; Peacock, S.J.; Prescott, H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. J. Am. Med. Assoc. 2020, 324, 782–793. [Google Scholar] [CrossRef]
- Chauhan, G.; Madou, M.J.; Kalra, S.; Chopra, V.; Ghosh, D.; Martinez-Chapa, S.O. Nanotechnology for COVID-19: Therapeutics and vaccine research. ACS Nano 2020, 14, 7760–7782. [Google Scholar] [CrossRef]
- Satija, S.; Mehta, M.; Sharma, M.; Prasher, P.; Gupta, G.; Chellappan, D.K.; Dua, K. Vesicular drug delivery systems as theranostics in COVID-19. Future Med. Chem. 2020, 12, 1607–1609. [Google Scholar] [CrossRef]
- Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020, 12, 372. [Google Scholar] [CrossRef] [Green Version]
- Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269–271. [Google Scholar] [CrossRef]
- Taddio, A.; Ipp, M.; Thivakaran, S.; Jamal, A.; Parikh, C.; Smart, S.; Sovran, J.; Stephens, D.; Katz, J. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine 2012, 30, 4807–4812. [Google Scholar] [CrossRef] [Green Version]
- Patki, M.; Palekar, S.; Reznik, S.; Patel, K. Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment. Int. J. Pharm. 2021, 597, 120329. [Google Scholar] [CrossRef]
- Skevaki, C.; Fragkou, P.C.; Cheng, C.; Xie, M.; Renz, H. Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus. J. Infect. 2020, 81, 205–212. [Google Scholar] [CrossRef]
- Tan, Q.; He, L.; Meng, X.; Wang, W.; Pan, H.; Yin, W.; Zhu, T.; Huang, X.; Shan, H. Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. J. Nanobiotechnol. 2021, 19, 173. [Google Scholar] [CrossRef]
- Pena-Silva, R.; Duffull, S.B.; Steer, A.C.; Jaramillo-Rincon, S.X.; Gwee, A.; Zhu, A. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br. J. Clin. Pharmacol. 2021, 87, 1589–1590. [Google Scholar] [CrossRef]
- Zheng, J.; Lu, C.; Ding, Y.; Zhang, J.; Tan, F.; Liu, J.; Yang, G.; Wang, Y.; Li, Z.; Yang, M.; et al. Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties. Int. J. Pharm. 2022, 619, 121719. [Google Scholar] [CrossRef]
- Brenner, J.S.; Mitragotri, S.; Muzykantov, V.R. Red blood cell hitchhiking: A novel approach for vascular delivery of nanocarriers. Annu. Rev. Biomed. Eng. 2021, 23, 225–248. [Google Scholar] [CrossRef]
- Katz, S.E.; Williams, D.J. Pediatric community-acquired pneumonia in the United States: Changing epidemiology, diagnostic and therapeutic challenges, and creas for future research. Infect. Dis. Clin. N. Am. 2018, 32, 47–63. [Google Scholar] [CrossRef]
- Grousd, J.A.; Rich, H.E.; Alcorn, J.F. Host-pathogen interactions in gram-positive bacterial pneumonia. Clin. Microbiol. Rev. 2019, 32, e00107-18. [Google Scholar] [CrossRef]
- Hageman, J.C.; Uyeki, T.M.; Francis, J.S.; Jernigan, D.B.; Wheeler, J.G.; Bridges, C.B.; Barenkamp, S.J.; Sievert, D.M.; Srinivasan, A.; Doherty, M.C.; et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–2004 influenza season. Emerg. Infect. Dis. 2006, 12, 894–899. [Google Scholar] [CrossRef]
- Diep, B.A.; Le, V.T.M.; Badiou, C.; Le, H.N.; Pinheiro, M.G.; Duong, A.H.; Wang, X.; Dip, E.C.; Aguiar-Alves, F.; Basuino, L.; et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci. Transl. Med. 2016, 8, 357ra124. [Google Scholar] [CrossRef] [Green Version]
- Flemming, H.; Wingender, J.; Szewzyk, U.; Steinberg, P.; Rice, S.A.; Kjelleberg, S. Biofilms: An emergent form of bacterial life. Nat. Rev. Microbiol. 2016, 14, 563–575. [Google Scholar] [CrossRef]
- Lin, X.; He, J.; Li, W.; Qi, Y.; Hu, H.; Zhang, D.; Xu, F.; Chen, X.; Zhou, M. Lung-targeting lysostaphin microspheres for methicillin-resistant Staphylococcus aureus pneumonia treatment and prevention. ACS Nano 2021, 15, 16625–16641. [Google Scholar] [CrossRef]
- Sievert, D.M.; Ricks, P.; Edwards, J.R.; Schneider, A.; Patel, J.; Srinivasan, A.; Kallen, A.; Limbago, B.; Fridkin, S. National healthcare safety network (NHSN) team and participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect. Control Hosp. Epidemiol. 2013, 34, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Brenwald, N.P.; Jevons, G.; Andrews, J.M.; Xiong, J.; Hawkey, P.M.; Wise, R. An outbreak of a CTX-M-type beta-lactamase-producing Klebsiella pneumoniae: The importance of using cefpodoxime to detect extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 2003, 51, 195–196. [Google Scholar] [CrossRef] [Green Version]
- Schaefers, M.M.; Duan, B.; Mizrahi, B.; Lu, R.; Reznor, G.; Kohane, D.S.; Priebe, G.P. PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. Vaccine 2018, 36, 6926–6932. [Google Scholar] [CrossRef]
- Qu, S.; Dai, C.; Yang, F.; Huang, T.; Hao, Z.; Tang, Q.; Wang, H.; Zhang, Y. Cefquinome-loaded microsphere formulations in protection against pneumonia with Klebsiella pneumonia Infection and inflammatory response in rats. Pharm. Res. 2019, 36, 74. [Google Scholar] [CrossRef]
- Mogharabi, M.; Abdollahi, M.; Faramarzi, M.A. Toxicity of nanomaterials; an undermined issue. DARU J. Pharm. Sci. 2014, 22, 59. [Google Scholar] [CrossRef] [Green Version]
- Provenzano, F.; Nyberg, S.; Giunti, D.; Torazza, C.; Parodi, B.; Bonifacino, T.; Usai, C.; Rosbo, N.K.D.; Milanese, M.; Uccelli, A.; et al. Micro-RNAs shuttled by extracellular vesicles secreted from mesenchymal stem cells dampen astrocyte pathological activation and support neuroprotection in in-vitro models of ALS. Cells 2022, 11, 3923. [Google Scholar] [CrossRef]
- Zhu, S.; Xing, H.; Gordiichuk, P.; Park, J.; Mirkin, C.A. PLGA spherical nucleic acids. Adv. Mater. 2018, 30, e1707113. [Google Scholar] [CrossRef]
- Ma, S.; Wang, C.; Dong, Y.; Jing, W.; Wei, P.; Peng, C.; Liu, Z.; Zhao, B.; Wang, Y. Microsphere-gel composite system with mesenchymal stem cell recruitment, antibacterial, and immunomodulatory properties promote bone regeneration via sequential release of LL37 and W9 peptides. ACS Appl. Mater. Interfaces 2022, 14, 38525–38540. [Google Scholar] [CrossRef]
- Bittner, B.; Ronneberger, B.; Zange, R.; Volland, C.; Anderson, J.M.; Kissel, T. Bovine serum albumin loaded poly(lactide-co-glycolide) microspheres: The influence of polymer purity on particle characteristics. J. Microencapsul. 1998, 15, 495–514. [Google Scholar] [CrossRef]
- Johansen, P.; Men, Y.; Audran, R.; Corradin, G.; Merkle, H.P.; Gander, B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 1998, 15, 1103–1110. [Google Scholar] [CrossRef]
- Kuzmov, A.; Minko, T. Nanotechnology approaches for inhalation treatment of lung diseases. J. Control Release 2015, 219, 500–518. [Google Scholar] [CrossRef] [Green Version]
- Bonner, J.C. Nanoparticles as a potential cause of pleural and interstitial lung disease. Proc. Am. Thorac. Soc. 2010, 7, 138–141. [Google Scholar] [CrossRef] [Green Version]
- Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [Google Scholar] [CrossRef]
- Hare, J.I.; Lammers, T.; Ashford, M.B.; Puri, S.; Storm, G.; Barry, S.T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38. [Google Scholar] [CrossRef] [Green Version]
- Jiang, H.L.; Jin, J.F.; Hu, Y.Q.; Zhu, K.J. Improvement of protein loading and modulation of protein release from poly(lactide-co-glycolide) microspheres by complexation of proteins with polyanions. J. Microencapsul. 2004, 21, 615–624. [Google Scholar] [CrossRef]
- Suk, J.S. Could recent advances in DNA-loaded nanoparticles lead to effective inhaled gene therapies? Nanomedicine 2016, 11, 193–196. [Google Scholar] [CrossRef]
- Lee, H.; Jeong, S.W.; Jung, E.; Lee, D. Dexamethasone-loaded H2O2-activatable anti-inflammatory nanoparticles for on-demand therapy of inflammatory respiratory diseases. Nanomedicine 2020, 30, 102301. [Google Scholar] [CrossRef]
- Hossen, S.; Hossain, M.K.; Basher, M.K.; Mia, M.N.H.; Rahman, M.T.; Uddin, M.J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 2019, 15, 1–18. [Google Scholar] [CrossRef]
- Wilhelm, S.; Tavares, A.J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H.F.; Chan, W.C.W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014. [Google Scholar] [CrossRef]
- Genchi, G.G.; Marino, A.; Tapeinos, C.; Ciofani, G. Smart materials meet multifunctional biomedical devices: Current and prospective implications for nanomedicine. Front. Bioeng. Biotechnol. 2017, 5, 80. [Google Scholar] [CrossRef] [Green Version]
Synthesis Method | Disease | Animal Model | Route of Administration | Ref. |
---|---|---|---|---|
Single and double emulsion | ALI/ARDS | Wistar rats | Intravenous injection | [72] |
Single and double emulsion | Wound healing | Diabetic rats | Gavage administration | [73] |
Single and double emulsion | Chronic glaucoma | Long Evans rats | Intracameral injection | [74] |
Single and double emulsion | Breast cancer | Female nude mice | Hypodermic injection | [75] |
Single and double emulsion | Myocardial infarction | Sprague–Dawley (SD) rats | Intravenous injection | [76] |
Single and double emulsion | CF | C57BL/6 mice | Pulmonary administration | [77] |
Single and double emulsion | CF | C57BL/6J female mice | Pulmonary administration | [78] |
Spray drying | Pneumonia | Mice | Intravenous injection | [79] |
Spray drying | Asthma | New Zealand rabbits | Intravenous injection | [80] |
Spray drying | ALI/ARDS | Male FVB/NJ mice | Intramuscular injection | [81] |
Spray drying | AIDS | Wistar rats | Gavage administration | [82] |
Precipitation | Cancer | BALB/C mice | Intravenous injection | [83] |
Precipitation | Glioblastoma | Wistar rats | Intravenous injection | [84] |
Precipitation | Wound healing | Wistar rats | Gavage administration | [85] |
Precipitation | Eye Inflammation | New Zealand rabbits | Ocular administration | [86] |
Precipitation | Glioma | mice | Intravenous injection | [87] |
Coacervation | Asthma | BALB/c mice | Pulmonary administration | [88] |
Coacervation | Derzsy’s disease | Muscovy duck | Subcutaneous injection | [89] |
Coacervation | Diphtheria | Guinea-pigs | Subcutaneous injection | [90] |
Coacervation | Fungal infection | Mice | Intravenous injection | [91] |
Coacervation | Cancer | Male Balb/c mice | Intravenous injection | [92] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guo, X.; Zuo, X.; Zhou, Z.; Gu, Y.; Zheng, H.; Wang, X.; Wang, G.; Xu, C.; Wang, F. PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases. Int. J. Mol. Sci. 2023, 24, 4333. https://doi.org/10.3390/ijms24054333
Guo X, Zuo X, Zhou Z, Gu Y, Zheng H, Wang X, Wang G, Xu C, Wang F. PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases. International Journal of Molecular Sciences. 2023; 24(5):4333. https://doi.org/10.3390/ijms24054333
Chicago/Turabian StyleGuo, Xiaoping, Xu Zuo, Zhengjie Zhou, Yinuo Gu, Haoyu Zheng, Xinlei Wang, Guoqiang Wang, Caina Xu, and Fang Wang. 2023. "PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases" International Journal of Molecular Sciences 24, no. 5: 4333. https://doi.org/10.3390/ijms24054333